Suellyn Rossman, MD
Allergy & Immunology · Des Plaines, ILNPI 1790773216
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by AstraZeneca at 46.9% of the total. Reporting peaked in 2019 at $9,501 and has fallen 87.6% since, to $1,182 in 2025.
Across 414 payments — averaging $54.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Genentech, Inc.$4K
- AbbVie$2K
- Genentech USA, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$967
- plus $3K from 17 others
What the payments were for
- Consulting fees$5,45024%
- Speaking & faculty fees$8,35037%
- Travel & lodging$5282%
- Food & beverage$8,28337%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 106 | $10,607 |
| Genentech, Inc. | 3 | $3,978 |
| AbbVie | 11 | $2,211 |
| Genentech USA, Inc. | 61 | $1,132 |
| Regeneron Healthcare Solutions, Inc. | 40 | $1,044 |
| GSK | 55 | $967 |
| Sanofi | 34 | $804 |
| Optinose US, Inc. | 31 | $434 |
| Novartis | 17 | $280 |
| Amgen | 15 | $266 |
| Boehringer Ingelheim | 9 | $247 |
| Pfizer | 9 | $197 |
| Teva Pharmaceuticals USA, Inc. | 4 | $99 |
| Sunovion Pharmaceuticals Inc. | 5 | $63 |
| Viatris Specialty LLC | 3 | $60 |
| Mylan Specialty L.p. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Kaleo, Inc. | 1 | $36 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| USWM, LLC | 1 | $17 |
| Greer Laboratories, Inc. | 1 | $16 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,618 in reported general payments places this provider in the 85th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZyfloZileuton | 17 | $90,304 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $67,392 |
| Zileuton ErZileuton | 11 | $45,950 |
| DuleraMometasone/Formoterol | 16 | $10,051 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $7,519 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,363 |
| AirsupraAlbuterol Sulfate/Budesonide | 12 | $5,450 |
| Cromolyn Sodium | 35 | $4,690 |
| Azelastine Hcl | 64 | $1,878 |
| Clobetasol Propionate | 13 | $1,613 |
| Montelukast Sodium | 98 | $1,221 |
| Moxifloxacin Hcl | 23 | $1,122 |
| Levocetirizine Dihydrochloride | 30 | $477 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $321 |
| Doxepin Hcl | 11 | $306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $967 | $81,273100 claims |
| MerckDulera | $12 | $10,05116 claims |
| AstraZenecaAirsupra | $10,607 | $5,45012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 161 allergy & immunology providers in Illinois.
Other allergy & immunology in Des Plaines
- Dareen SiriNormal$1.5M
- Priya BansalSaint Charles$1.3M
- Anju PetersChicago$563K
- Giselle MosnaimChicago$331K
- Patrick WinShiloh$258K
- Amanda SalihChicago$160K
- Rebecca HoffmanWilmette$160K
- Juanita MoraChicago$147K
- Sonali MajmudarAlgonquin$136K
- Zachary RubinElmhurst$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.